Weight loss following lisdexamfetamine in children and adolescents with attention deficit hyperactivity disorder and overweight and obesity.

IF 2.7 3区医学 Q1 PEDIATRICS

Pediatric Obesity Pub Date : 2025-05-15 DOI:10.1111/ijpo.70024

Mostafa Salama, Kaitlin Leopold, Roland Hentz, Seema Kumar

{"title":"Weight loss following lisdexamfetamine in children and adolescents with attention deficit hyperactivity disorder and overweight and obesity.","authors":"Mostafa Salama, Kaitlin Leopold, Roland Hentz, Seema Kumar","doi":"10.1111/ijpo.70024","DOIUrl":null,"url":null,"abstract":"Objective: To examine change in weight status following initiation of lisdexamfetamine in children with attention deficit hyperactivity disorder (ADHD) and overweight or obesity.Study design: A retrospective chart review included children aged 2 to <18 years treated with lisdexamfetamine for ADHD. Body mass index (BMI) data for up to 2 years after initiation of lisdexamfetamine were analysed using linear mixed effects models with autoregressive-1 correlation structure on time of follow-up per patient.Results: The analysis included 330 children ≤18 years, median age 10 years (interquartile range 8.1-13) comprising 55 children with severe obesity, 88 with mild-moderate obesity, 131 with overweight and 56 with healthy weight, 68% male and 32% female. At 2 years after initiation of lisdexamfetamine in the severe obesity group, the BMI Z-score decreased by -0.41 (95% confidence intervals [CI] [-0.57, -0.25], p < 0.001) and BMI percent of the 95th percentile decreased by -11.2% (95% CI [-15.8 to -6.7], p < 0.001). In the mild-moderate obesity group, BMI Z-score decreased by -0.44 (95% CI [-0.56, -0.31], p < 0.001) and BMI% of the 95th percentile decreased by -11.1% at 24 months (95% CI [-13.9 to -8.4], p < 0.001). In the mild-moderate obesity and overweight groups, younger children (ages 4-10) showed greater reduction in their BMI (p < 0.001 and p = 0.029, respectively).Conclusion: Reduction in BMI for age was noted for up to 2 years following initiation of lisdexamfetamine in children with ADHD and overweight and obesity. Further studies are warranted to study the weight loss effect of lisdexamfetamine in children with obesity.","PeriodicalId":217,"journal":{"name":"Pediatric Obesity","volume":" ","pages":"e70024"},"PeriodicalIF":2.7000,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Obesity","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/ijpo.70024","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PEDIATRICS","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To examine change in weight status following initiation of lisdexamfetamine in children with attention deficit hyperactivity disorder (ADHD) and overweight or obesity.

Study design: A retrospective chart review included children aged 2 to <18 years treated with lisdexamfetamine for ADHD. Body mass index (BMI) data for up to 2 years after initiation of lisdexamfetamine were analysed using linear mixed effects models with autoregressive-1 correlation structure on time of follow-up per patient.

Results: The analysis included 330 children ≤18 years, median age 10 years (interquartile range 8.1-13) comprising 55 children with severe obesity, 88 with mild-moderate obesity, 131 with overweight and 56 with healthy weight, 68% male and 32% female. At 2 years after initiation of lisdexamfetamine in the severe obesity group, the BMI Z-score decreased by -0.41 (95% confidence intervals [CI] [-0.57, -0.25], p < 0.001) and BMI percent of the 95th percentile decreased by -11.2% (95% CI [-15.8 to -6.7], p < 0.001). In the mild-moderate obesity group, BMI Z-score decreased by -0.44 (95% CI [-0.56, -0.31], p < 0.001) and BMI% of the 95th percentile decreased by -11.1% at 24 months (95% CI [-13.9 to -8.4], p < 0.001). In the mild-moderate obesity and overweight groups, younger children (ages 4-10) showed greater reduction in their BMI (p < 0.001 and p = 0.029, respectively).

Conclusion: Reduction in BMI for age was noted for up to 2 years following initiation of lisdexamfetamine in children with ADHD and overweight and obesity. Further studies are warranted to study the weight loss effect of lisdexamfetamine in children with obesity.

查看原文本刊更多论文

患有注意缺陷多动障碍、超重和肥胖的儿童和青少年服用利地胺后体重减轻。

目的：研究患有注意缺陷多动障碍（ADHD）和超重或肥胖的儿童开始服用利地氨苯他明后体重状况的变化。研究设计：回顾性图表分析纳入2至32%的儿童。结果：分析纳入330名≤18岁的儿童，中位年龄为10岁（四分位数范围8.1-13），其中重度肥胖儿童55名，轻度-中度肥胖儿童88名，超重儿童131名，健康体重儿童56名，男性68%，女性32%。在重度肥胖组开始使用利地氨苯胺2年后，BMI z评分下降了-0.41（95%可信区间[CI] [-0.57, -0.25], p）。结论：在患有ADHD、超重和肥胖的儿童中，利地氨苯胺开始使用利地氨苯胺后长达2年的时间里，BMI随年龄的下降都是明显的。利地安非他明对肥胖儿童的减肥效果有待进一步研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pediatric Obesity PEDIATRICS-

CiteScore

7.30

自引率

5.30%

发文量

117

审稿时长

6-12 weeks

期刊介绍： Pediatric Obesity is a peer-reviewed, monthly journal devoted to research into obesity during childhood and adolescence. The topic is currently at the centre of intense interest in the scientific community, and is of increasing concern to health policy-makers and the public at large. Pediatric Obesity has established itself as the leading journal for high quality papers in this field, including, but not limited to, the following: Genetic, molecular, biochemical and physiological aspects of obesity – basic, applied and clinical studies relating to mechanisms of the development of obesity throughout the life course and the consequent effects of obesity on health outcomes Metabolic consequences of child and adolescent obesity Epidemiological and population-based studies of child and adolescent overweight and obesity Measurement and diagnostic issues in assessing child and adolescent adiposity, physical activity and nutrition Clinical management of children and adolescents with obesity including studies of treatment and prevention Co-morbidities linked to child and adolescent obesity – mechanisms, assessment, and treatment Life-cycle factors eg familial, intrauterine and developmental aspects of child and adolescent obesity Nutrition security and the "double burden" of obesity and malnutrition Health promotion strategies around the issues of obesity, nutrition and physical activity in children and adolescents Community and public health measures to prevent overweight and obesity in children and adolescents.